

RECEIVED
CENTRAL FAX CENTER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FEB 18 2004

OFFICIAL

Appellant: Monty Krieger

Serial No.: 09/148,012

Art Unit: 1647

Filed: September 4, 1998

Examiner: Robert S. Landsman

For: *SR-BI ANTAGONIST AND USE THEREOF AS CONTRACEPTIVES AND IN THE
TREATMENT OF STEROIDAL OVERPRODUCTION*Mail Stop Appeal Brief - Patents
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**REPLY BRIEF**

Sir:

This is a Brief in reply to the Examiner's Answer mailed December 18, 2003 in the above-identified patent application. A Request for Oral Hearing accompanies this Answer along with the appropriate fee. It is believed that no additional fee is required with this submission. However, should an additional fee be required, the Commissioner is hereby authorized to charge the fee to Deposit Account No. 50-1868.

(2) RELATED APPEALS AND INTERFERENCES

On page 2 of the appeal brief filed September 19, 2003 under the section entitled "(2) RELATED APPEALS AND INTERFERENCES" it is expressly stated that there are no related appeals or interferences known to appellant, the undersigned, or appellant's assignee which directly affects, which would be directly affected by, or which would have a bearing on the Board's decision in this appeal.

U.S.S.N. 09/148,012
Filed: September 4, 1998
REPLY BRIEF

(8) ARGUMENTS

Response to Examiner's Arguments

Appellant maintains that the invention is a pioneering invention - the discovery that abnormal levels of lipoproteins and/or cholesterol levels can negatively affect fertility, and that altering lipoprotein and/or cholesterol levels can affect a female's ability to reproduce. The Appellant has developed a method to alter a female's ability to reproduce by altering serum levels of lipoproteins, LDL, HDL and/or cholesterol. This method has applications for contraception as well as in treating fertility disorders. The example in the application uses an acceptable animal model for control of fertility in humans - the mouse, to demonstrate that administration of a drug known to control cholesterol in humans can be used to restore fertility in the females, allowing animals to conceive and carry to full term babies, as compared to the controls that were completely unable to do so. Measurements of the lipoproteins and cholesterol show much more normalized levels in those animals in whom fertility was restored. The mechanism of action is still not completely clear, but it is important to note that it was a drug already approved for use in humans to lower cholesterol that was used in an animal model that is commonly used to screen drugs for human use.

(i) Rejections Under 35 U.S.C. § 112, first paragraph (written description)

The Examiner is confused by the mechanism of SR-BI action described in the Appeal Brief. To clarify the mechanism of SRBI action, a decrease in SRBI causes an increase in cholesterol levels. On page 5, paragraph 3 of the Appeal Brief, the sentence should read "that

U.S.S.N. 09/148,012
Filed: September 4, 1998
REPLY BRIEF

decreasing levels of SR-BI activity *increases* cholesterol levels and alters lipoprotein levels;”.

Page 12 of the specification states that SR-BI is a scavenger receptor protein that transports cholesterol from the blood into tissues such as liver and steroidogenic tissues thus decreasing plasma levels of cholesterol. In situations where SRBI expression is reduced or SRBI function is blocked (as in a knockout mouse), plasma cholesterol levels increase.

The claims are directed to a method “to alter fertility or treat a reproductive disorder”.

One of skill in the art would comprehend that the term “alter” indicates that fertility can be either reduced or enhanced. Fertility reductions would be desirable for methods of contraception as described on page 13, lines 8-15 of the specification, and Example 6. Enhancement of fertility would be desirable for situations where a fertility disorder prevents reproduction. Example 5 demonstrates that enhancement of SRBI function reduces plasma cholesterol levels. Claims 2, 4 and 5 are directed to altering SRBI expression to reduce or enhance fertility. Claims 3, 6 and 7 are directed to altering SRBI binding to reduce or enhance fertility. The specification makes it very clear in which direction SR-BI must be altered to alter fertility or treat a reproductive disorder. There is no ambiguity. The method principles and steps are adequately described by the specification in view of the knowledge in the art.

(ii) Rejections Under 35 U.S.C. § 112, first paragraph (enablement)

As described above, the claims are directed to modulating fertility by increasing or decreasing the activity of SR-BI. The claims are enabled because the Appellant has described specifically which direction one would need to alter cholesterol and lipoprotein levels in order to increase or decrease fertility. The Appellant has established a connection between cholesterol

U.S.S.N. 09/148,012
Filed: September 4, 1998
REPLY BRIEF

and lipoprotein levels and fertility. The Appellant has provided an example (although none are required) to show a decrease in fertility after inhibiting SR-BI function and increasing serum cholesterol levels. The Appellant has submitted an article by Miettinen et al. to demonstrate that using the same methods and concepts taught by the specification, fertility can be restored.

The Examiner asserts that there is no evidence that women taking cholesterol-lowering drugs exhibit fertility problems. First, it should be noted that there are many causes of infertility. Appellant is not claiming a method of treatment of all types of infertility. Second, cholesterol-lowering drugs are not recommended for administration to women who may be pregnant or trying to become pregnant. (See attached article – there is a definite risk to the fetus from taking cholesterol lowering drugs based on this information). High cholesterol is a problem that develops in women during and following menopause, when estrogen levels decrease significantly. (See attached article)

The role of serum cholesterol levels on fertility is described on page 50 of the specification. The infertile SR-BI knockout mice have extremely elevated cholesterol levels and totally abnormal lipoprotein levels. By decreasing serum cholesterol levels and normalizing lipoprotein levels, one can enhance fertility.

(iii) Rejections Under 35 U.S.C. § 112, second paragraph

The claims are definite and include all necessary steps to practice the claimed method. The treatment regimen is already defined in the claim where the term “an effective amount” is administered. One of skill in the art would understand this “amount” in view of the teachings on

U.S.S.N. 09/148,012
Filed: September 4, 1998
REPLY BRIEF

pages 26 and 27 of the specification and knowledge in the art of dose titration and the use of animal models.

The term "to enhance" fertility relates to the process of implantation and development of the embryo. This is described on page 8, lines 8-9 of the specification, where studies demonstrate that infertile females do not produce viable eggs and have a defect involving implantation of the fertilized egg. "Enhancement" refers to an improvement in the viability of the eggs or the ability of a fertilized egg to implant in the uterine wall. One of skill in the art would understand that fertility is a physiological state where the conditions are optimum for initial fertilization, implantation and growth of an embryo. This is why the term "enhanced" is more appropriate than "restored" because a certain threshold of these conditions is required for fertility. One of skill in the art would understand that an improvement in these conditions would constitute an enhancement of fertility. Similarly anything that compromises these conditions would constitute a reduction of fertility.

U.S.S.N. 09/148,012
Filed: September 4, 1998
REPLY BRIEF

(9) SUMMARY AND CONCLUSION

For the foregoing reasons, Appellant submits that the claims 1-10, 12, 15, 16 and 20-22 are patentable.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Date: February 18, 2004

HOLLAND & KNIGHT LLP
One Atlantic Center, Suite 2000
1201 West Peachtree Street
Atlanta, Georgia 30309-3400
(404) 817-8473
(404) 817-8588 (Fax)

Certificate of Facsimile Transmission

I hereby certify that this Request for Oral Hearing, Reply Brief, and any documents referred to as attached therein are being facsimile transmitted on this date, February 18, 2004, to Mail Stop Appeal Brief-Patents, Commissioner for Patents, Alexandria, VA 22313-1450.



Patrea Pabst

Date: February 18, 2004

June 200

Canadian Family Physician

français

my CFP • information for authors • about CFP • pdf • cover page •

Search CFP

SEARCH

Advanced search...

Contents

Editorials

Letters

Clinical Challenge

Critical Appraisal

CME

Research

Resources

News

Vital Signs

• Other issues:

• Other years:

CLINICAL CHALLENGE

MOTHERISK UPDATE

Use of lipid-lowering agents (statins) during pregnancy

Akiko Hosokawa, MD Benjamin Bar-Oz, MD Shinya Ito, MD

ABSTRACT

QUESTION A 34-year-old patient of mine is taking a "statin" for hyperlipidemia. She is planning pregnancy and is worried about the safety of the drug. How should I advise her?
ANSWER Limited evidence from animal and human studies indicates that statins should not be taken during pregnancy. If a patient is inadvertently exposed during pregnancy, however, termination does not appear to be medically indicated.

RÉSUMÉ

QUESTION Une de mes patientes prend des « statines » contre l'hyperlipidémie. Elle planifie une grossesse et s'inquiète à propos de la sécurité de ce médicament. Comment puis-je la conseiller?

RÉPONSE Des données scientifiques limitées, tirées d'études chez les animaux et les humains, indiquent que les statines ne devraient pas être prises durant la grossesse. Si une patiente était exposée à ce médicament par inadvertance pendant qu'elle est enceinte, il n'est cependant pas indiqué sur le plan médical de mettre un terme à la grossesse.

"Statins," β -hydroxy- β -methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, have been widely used for treatment of hyperlipidemia and for reducing morbidity and mortality coronary artery disease (CAD).¹⁻⁵ Current recommendations suggest discontinuing the medication before conception,⁶ especially since stopping therapy for the relatively short duration of pregnancy is believed to have little effect on long-term outcome.⁷ If a patient becomes pregnant while taking the medication, there are no clear guidelines to follow.

Pharmacology of HMG-CoA reductase inhibitors

The HMG-CoA reductase inhibitors currently marketed for clinical use include atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin (cerivastatin was withdrawn from the market because of reports of fatal rhabdomyolysis; it will not be discussed further). The medications reduce the intracellular concentration of cholesterol and result in an increase in the activity of low-density lipoprotein cholesterol (LDL-C) receptors that enhances the uptake

Use of lipid-lowering agents (statins) during pregnancy

and catabolism of LDL-c.⁸ Clinical trials have shown that all the statins significantly improve various lipid parameters including LDL-c, high-density lipoprotein cholesterol, and triglycerides.^{9,10} More importantly, summarized results of both angiographic and clinical trials have shown that aggressively lowering LDL-c by at least 25% with statin therapy can delay progression of CAD and decrease the incidence of nonfatal myocardial infarction and death from CAD.^{9,11}

Effects of maternal hypercholesterolemia on a fetus

A growing body of evidence suggests that maternal hypercholesterolemia is associated with development of fetal atherosclerosis. Napoli et al¹² found that fetal aortas from hypercholesterolemic mothers (mean plasma cholesterol 292 mg/dL before pregnancy and 385 mg/dL during pregnancy) contain a significantly higher number of fatty streak lesions and are larger than fetal aortas from mothers with normal cholesterol levels (total plasma cholesterol < 185 to 200 mg/dL, depending on age).

This difference was even found for mothers who were hypercholesterolemic only during pregnancy. The authors also discovered that the lesions got significantly larger with advancing age beyond 1 year and that the rate of progression was faster in children of hypercholesterolemic mothers. The difference in the rate could not be attributed to the children's cholesterol levels because they were found to be normal. The findings of these studies have been confirmed in animal models.^{13,14}

Interventions to reduce cholesterol and lipid oxidation, including cholestyramine and vitamin E therapy, significantly reduce lesions at birth.^{14,15} These findings suggest the importance of maternal cholesterol levels in the pathogenesis of atherosclerosis in children, but their clinical importance is still unknown.

Fetal toxicity associated with statins

Atorvastatin (Lipitor). No teratogenic effects of atorvastatin were seen in rats and rabbits even at maternally toxic doses, although fetal body weight was lower than normal.¹⁵ Another study in rats showed that atorvastatin at maternally toxic doses resulted in a 45% low survival rate of the offspring, decreased body weight, and abnormal neonatal development.

No data on human pregnancies have been published. We located eight cases in our Mother database of statin use during the first trimester of pregnancy. Among these cases, there were two spontaneous abortions, one premature neonatal death (at 24 weeks' gestation), one elective abortion, two normal outcomes, and two patients lost to follow up. Given the limited information available, atorvastatin should be avoided during pregnancy.

Fluvastatin (Lescol). Manufacturer's data showed no evidence of teratogenicity in rats and rabbits given high doses of fluvastatin. The same researchers showed, however, that high doses of fluvastatin resulted in maternal mortality secondary to cardiomyopathy, weight loss, decreased neonatal weight gain, and an increased incidence of stillbirths and neonatal deaths.^{17,18}

Sandoz Pharmaceuticals (manufacturer of Lescol) reported on five human pregnancies. There were two normal outcomes, one ectopic pregnancy, one spontaneous abortion, and one unknown outcome. Duration and timing of drug exposure were not mentioned. An additional report described a 28-year-old woman taking medications, including fluvastatin during her first trimester, who delivered a normal, full-term, healthy infant. Given the evidence to date (ie, maternal mortality in animal models), however, fluvastatin should be avoided during pregnancy.

Lovastatin (eg, Mevacor). Administration of lovastatin to pregnant rats at doses of 8 mg/kg daily resulted in decreased maternal weight gain, fetal skeletal malformations (including vertebrae and ribs), and gastroschisis.¹⁹ No drug-induced changes were seen

Use of lipid-lowering agents (statins) during pregnancy

rabbits or mice given lovastatin at doses nine to 50 times the maximum recommended dose for humans.²⁰

A postmarketing surveillance study⁷ reported on 48 cases with known outcome of women using lovastatin during pregnancy. There were three (6.3%) spontaneous abortions, 0 (2.1%) stillbirth, four (8.3%) infants with congenital anomalies (atrial or ventricular septal defects, cerebral dysfunction, VATER complex, spina bifida, and holoprosencephaly), (81.2%) normal outcomes, and one case of pedal edema. Based on the timing of exposure and diversity of malformations, there is likely no causal relationship between taking the drug and congenital anomalies.⁷

Pravastatin (Pravachol). High doses of pravastatin administered to rats and rabbits had teratogenic effects.^{21,22} No data on human use of pravastatin during pregnancy have been published. The manufacturer, Bristol-Myers Squibb, has, however, received 26 case reports of exposure during pregnancy. Among these, 11 were exposed during the first trimester, and had normal pregnancy outcomes (personal communication from Bristol-Myers Squibb Canada, November 12, 1996). Animal data and known human exposures indicate that pravastatin does not increase the risk of major congenital anomalies.

Simvastatin (Zocor). Animal studies using both rats and rabbits demonstrated a teratogenic effect of high doses of simvastatin.^{23,24} Toxic doses, however, resulted in maternal weight loss and an increased resorption rate in rabbits.²⁵ In contrast, high doses resulted in decreased mean fetal body weight and maternal weight gain in rats.²⁵ Postmarketing surveillance data are available on 86 cases with known pregnancy outcome following exposure to simvastatin.⁷ Among these cases, there were 13 (15.1%) spontaneous abortions, one (1.2%) fetal death, five (5.8%) congenital anomalies (polydactyly, unilateral cleft lip, balanitis hypospadias, trisomy 18, and clubfoot), three (3.5%) miscellaneous adverse outcomes possibly related to prematurity, and 64 (74%) normal outcomes. Based on animal and human data, exposure to simvastatin during pregnancy does not appear to increase the risk of congenital malformations.

Conclusion

Results of animal studies indicate that many statins are associated with adverse fetal outcomes at maternally toxic doses. The limited human data suggest that statins are not major human teratogens.⁷ Thus, if women are inadvertently exposed to statins before recognition of pregnancy, they can be reassured that their fetuses do not appear to be at increased risk.

Nonetheless, it seems reasonable to follow the current recommendation of discontinuing lipid-lowering medication immediately upon recognition of pregnancy or before conception if pregnancy was planned.^{6,19,21,27,28} With new evidence to suggest that maternal hypercholesterolemia has a detrimental effect on a developing fetus, this recommendation might change, particularly in light of the results of further studies of statins and other agents, such as vitamin E, during pregnancy, when they become available.

Published monthly by
The College of Family
Physicians of Canada.
2630 Skymark Ave,
Mississauga,
ON, L4W5A4
Telephone
(905) 629-0900
Fax (905) 629-0893
Website
<http://www.cfpc.ca>

Montreal office
104 Lisbonne,
Dollard-des-Ormeaux,
QC H9B 3B7

References

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med* 1995;333(20):1301-7.
2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA* 1998;279(20):1615-22.
3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994;344(8934):1383-9.
4. Sacks F, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med* 1996;335(14):1001-9.

5. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevent of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. *N Engl J Med* 1998;339(19):1349-57.
6. Miller V. Dyslipoproteinemia in women. *Endocrinol Metab Clin North Am* 1990;19:381-98.
7. Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. *Reprod Toxicol* 1996;10(6):439-46.
8. Malloy MJ, Kane JP. Agents used in hyperlipidemia. In: Katzung BG, editor. Basic and clinical pharmacology. 6th ed. Norwalk, Conn: Appleton and Lange; 1995. p. 522-35.
9. Blumenthal RS. Statins: effective antiatherosclerotic therapy. *Am Heart J* 2000;139:577-83.
10. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. *Am J Card* 1998;81(Suppl 4A):66B-9B.
11. Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. *Am J Card* 1998;82(Suppl 9A):3Q-12Q.
12. Napoli C, D'Armiento FP, Mancini FP, Postiglioni A, Witztum JL, Palumbo G, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment in early atherosclerotic lesions. *J Clin Invest* 1997;100(11):2680-90.
13. Napoli C, Witztum JL, Calara F, de Nigris F, Palinski G. Maternal hypercholesterolemia enhances atherogenesis in normocholesterolemic rabbits, which is inhibited by antioxidant or lipid-lowering intervention during pregnancy: an experimental model of atherogenic mechanisms in human fetus. *Circ Res* 2000;87:946-52.
14. Palinski W, D'Armiento FP, Witztum JL, de Nigris F, Casanada F, Condorelli M, et al. Maternal hypercholesterolemia and treatment during pregnancy influence the long-term progression of atherosclerosis in offspring of rabbits. *Circ Res* 2001;89:991-6.
15. Dostal LA, Schardein JL, Anderson JA. Developmental toxicity of the HMG-CoA reductase inhibitor atorvastatin, in rats and rabbits. *Teratology* 1994;50:387-94.
16. Henck JW, Craft WR, Black A, Colgin A, Anderson JA. Pre- and postnatal toxicity of the HMG-C reductase inhibitor atorvastatin in rats. *Toxicol Sci* 1998;41:88-99.
17. Hrab RV, Hartman HA, Cox RH. Prevention of fluvastatin-induced toxicity, mortality, and cardiomyopathy in pregnant rats by mevalonic acid supplementation. *Teratology* 1994;50:19-29.
18. Sandoz Canada Inc, Astra Pharma Inc. Pharmacokinetics. In: Product monograph. Lesz fluvastatin sodium. Dorval, Que, Mississauga, Ont: Sandoz Canada Inc, Astra Pharma Inc; 1993. p. 11.
19. Minsker DH, MacDonald JS, Robertson RT, Bokelman DL. Mevalonate supplementation pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy methylglutaryl-coenzyme A reductase. *Teratology* 1983;28:449-56.
20. Merck Frosst Canada Inc. Pharmacokinetics. In: Product monograph. Mevacor: lovastatin. Kirkland, Que: Merck Frosst Canada Inc; 1991. p. 1-19.
21. Tanase TM, Hirose K. Reproduction studies of pravastatin sodium administered during the period of fetal organogenesis in rats. *Yakuri to Chiryō* 1987;15(12):4983-94.
22. Tanase TM, Asai M, Hirose K. Reproduction studies of pravastatin sodium administered during period of fetal organogenesis in rabbits. *Yakuri to Chiryō* 1987;15(12):5005-11.
23. Wise LD, Majka JA, Robertson RT, Bokelman DL, Nakatsuka T, Akutsu S, et al. Simvastatin (MK-0733): oral teratogenicity study in rats. Pre- and postnatal observation. *Yakuri to Chiryō* 1990; (2):143-58.
24. Wise LD, Prahalada S, Robertson RT, Bokelman DL, Akutsu S, Fujii T. Simvastatin (MK-0733) c teratogenicity study in rabbits. *Yakuri to Chiryō* 1990;39(2):159-67.
25. Minsker DH, Robertson RT, Bokelman DL. Simvastatin (MK-0733): oral late gestation and lactation study in rats. *Yakuri to Chiryō* 1990;39(2):169-79.
26. Wise LD, Minsker DH, Robertson RT, Bokelman DL, Akutsu S, Fujii T. Simvastatin (MK-0733): c fertility study in rats. *Yakuri to Chiryō* 1990;39(2):127-41.
27. Warner-Lambert Canada Inc. Human pharmacokinetics. In: Product monograph. Lipit atorvastatin calcium. Scarborough, Ont: Warner-Lambert Canada Inc; 2000. p. 1-42.
28. Squibb Canada Inc. Pharmacokinetics. In: Product monograph. Pravachol: pravastatin sodium. Montreal, Que: Squibb Canada Inc; 1990. p. 1-38.

Motherisk questions are prepared by the Motherisk Team at the Hospital for Sick Children Toronto, Ont. **Drs Bar-Oz and Ito** are members of the Motherisk Program. **Dr Hosokawa** a resident in the family medicine program at the University of Toronto.

Do you have questions about the safety of drugs, chemicals, radiation, or infections in women who are pregnant or breastfeeding? We invite you to submit them to the Motherisk Program by fax at (416) 813-7562; they will be addressed in future Motherisk Update. Published Motherisk Updates are available on the College of Family Physicians of Canada website (www.cfpc.ca). Some articles are published in The Motherisk Newsletter and on the Motherisk website (www.motherisk.org) also.

What Are Healthy Levels of Cholesterol?

[ADVANCED SEARCH](#)[SEARCH](#)[DONATE](#) [HELP](#) [CONTACT](#) [SITE INDEX](#) [HOME](#)

February 18, 2004

**American I
Associ**
Learn[Main Menu](#)[Diseases &
Conditions](#)[Cholesterol](#)[About Cholesterol](#)[What are Healthy
Levels of
Cholesterol?](#)**What Are Healthy Levels of Cholesterol?**

Your total blood cholesterol level
Your total blood cholesterol will fall into one of these categories:

Desirable — Less than 200 mg/dL
Borderline high risk — 200-239 mg/dL
High risk — 240 mg/dL and over

Here is some more explanation about each of these categories.

Desirable

If your total cholesterol is less than 200 mg/dL, your heart attack risk is relatively low, unless you have other risk factors. Even with a low risk, it's still smart to eat foods low in saturated fat and cholesterol, and also get plenty of physical activity. Have your cholesterol levels measured every five years — or more often if you're a man over 45 or a woman over 55.

Borderline high risk

People whose cholesterol level is from 200 to 239 mg/dL are borderline high risk. About a third of American adults are in this (borderline) group; almost half of adults have total cholesterol levels below 200 mg/dL.

Have your cholesterol and HDL rechecked in one to two years if:

- Your total cholesterol is in this range
- Your HDL is less than 40 mg/dL
- You don't have other risk factors for heart disease

You should also lower your intake of foods high in saturated fat and cholesterol to reduce your blood cholesterol level to below 200 mg/dL. Your doctor may order another blood test to measure your LDL cholesterol. Ask your doctor to discuss your LDL cholesterol with you. Even if your total cholesterol is between 200 and 239 mg/dL, you may not be at high risk for a heart attack. Some people — such as women before menopause and young, active men who have no other risk factors — may have high HDL cholesterol and desirable LDL levels. Ask your doctor to interpret your results. Everyone's case is different.

High risk

If your total cholesterol level is 240 or more, it's definitely high. Your risk of heart attack and stroke is greater. In general, people who have a total cholesterol level of 240 mg/dL have twice the risk of heart attack as people whose cholesterol level is 200 mg/dL.

You need more tests. Ask your doctor for advice. About 20 percent of the U.S. population has high blood cholesterol levels.

Your LDL cholesterol level

Your LDL cholesterol level greatly affects your risk of heart attack and stroke. The lower your LDL cholesterol, the lower your risk. In fact, it's

RELATED IT[Links on This
Test Your Chol](#)[Common Misc
About Cholest](#)[Cholesterol Tre](#)[Risk Factors fo
Heart Disease](#)[Special Messa](#)**DID YOU K**

105 million Am
total cholestero
or higher, a lev
cardiovascular
rise.

[read more...](#)

What Are Healthy Levels of Cholesterol?

Page 2 of 3

a better gauge of risk than total blood cholesterol. Your LDL cholesterol will fall into one of these categories:

LDL Cholesterol Levels

Less than 100 mg/dL	Optimal
100 to 129 mg/dL	Near Optimal/ Above Optimal
130 to 159 mg/dL	Borderline High
160 to 189 mg/dL	High
190 mg/dL and above	Very High

The key point to remember is, the lower your LDL cholesterol, the lower your risk. Your doctor may prescribe a diet low in saturated fat and cholesterol, regular exercise and a weight management program if you're overweight. If you can't lower your cholesterol with these efforts, medications may also be prescribed to lower your LDL cholesterol. Check these categories and the goals for treatment that can lower your risk of heart attack.

LDL level at which to consider drug therapy

	LDL Level	Goal
People without coronary heart disease and with fewer than two risk factors	190 mg/dL or higher*	160 mg/dL or lower
People without coronary heart disease and with two or more risk factors	160 mg/dL or higher	130 mg/dL or lower
People with coronary heart disease	130 mg/dL or higher**	100 mg/dL or lower

**In men less than age 35 and premenopausal women with LDL cholesterol levels of 190 to 219 mg/dL, drug therapy should be delayed except in high-risk patients such as those with diabetes.*

***In coronary heart disease patients with LDL cholesterol levels of 100 to 129 mg/dL, the doctor should consider whether to initiate drug treatment in addition to the American Heart Association Therapeutic Lifestyle Changes (TLC) diet.*

If you don't know if you have other risk factors for heart disease, check out the American Heart Association's list by [clicking here](#).

Your HDL cholesterol level

In the average man, HDL cholesterol levels range from 40 to 50 mg/dL. In the average woman, they range from 50 to 60 mg/dL. HDL cholesterol that's less than 40 mg/dL is low. Low HDL cholesterol puts you at high risk for heart disease. Smoking, being overweight and being sedentary can all result in lower HDL cholesterol. If you have low HDL cholesterol, you can help raise it by:

- Not smoking
- Losing weight (or maintaining a healthy weight)

What Are Healthy Levels of Cholesterol?

- Being physically active for at least 30–60 minutes a day on most or all days of the week

People with high blood triglycerides usually have lower HDL cholesterol and a higher risk of heart attack and stroke. Progesterone, anabolic steroids and male sex hormones (testosterone) also lower HDL cholesterol levels. Female sex hormones raise HDL cholesterol levels.

Cholesterol ratio

Total blood cholesterol is the most common measurement of blood cholesterol. It's the number you normally receive as test results. Cholesterol is measured in milligrams per deciliter of blood (mg/dL). Knowing your total blood cholesterol level is an important first step in determining your risk for heart disease. However, a critical second step is knowing your HDL or "good" cholesterol level.

Some physicians and cholesterol technicians use the ratio of total cholesterol to HDL cholesterol in place of the total blood cholesterol. The American Heart Association recommends that the absolute numbers for total blood cholesterol and HDL cholesterol levels be used. They're more useful to the physician than the cholesterol ratio in determining the appropriate treatment for patients.

The ratio is obtained by dividing the HDL cholesterol level into the total cholesterol. For example, if a person has a total cholesterol of 200 mg/dL and an HDL cholesterol level of 50 mg/dL, the ratio would be stated as 4:1. The goal is to keep the ratio below 5:1; the optimum ratio is 3.5:1.

Your triglyceride level

Your triglyceride level will fall into one of these categories:

Triglyceride Level	Classification
Less than 150 mg/dL	Normal
150–199 mg/dL	Borderline-high
200–499 mg/dL	High
500 mg/dL or higher	Very high

Many people with high triglycerides have underlying diseases or genetic disorders. If this is true for you, the main therapy is to change your lifestyle. This includes controlling your weight, eating foods low in saturated fat and cholesterol, exercising regularly, not smoking and, in some cases, drinking less alcohol. People with high triglycerides may also need to limit their intake of carbohydrates to no more than 45–50 percent of total calories. The reason for this is that carbohydrates raise triglycerides in some people and lower HDL cholesterol. Use products with monounsaturated and polyunsaturated fats.

Privacy Statement | Use of Personal Information | Copyright

©2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.